G-Ergometrine Injection 0.2 mg/ml Uses, Dosage, Side Effects and more

G-Ergometrine Injection 0.2 mg/ml Uses, Dosage, Side Effects, Food Interaction and all others data.

Table Of contents

• G-Ergometrine Injection 0.2 mg/ml
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	G-Ergometrine Injection 0.2 mg/ml
Generic	Ergometrine Maleate
Weight	0.2 mg/ml
Type	Injection
Therapeutic Class	Drugs acting on the Uterus
Manufacturer	Gonoshasthaya Pharma Ltd.
Available Country	Bangladesh
Last Updated:	January 7, 2025 at 1:49 am

Uses

Active management of the third stage of labour, Treatment and prophylaxis of postpartum haemorrhage, Excessive uterine bleeding, Postpartum and post-abortion bleeding

Dosage

G-Ergometrine Injection 0.2 mg/ml dosage

Intramuscular (Adult)- Active management of the third stage of labour: 0.5 mg given with 5 units of oxytocin after delivery of the anterior shoulder of the infant or immediately after delivery. Treatment and prophylaxis of postpartum haemorrhage: 0.2 mg, may repeat in severe bleeding every 2-4 hr as needed. Intravenous(Adult)- Excessive uterine bleeding: 0.2 mg via IV inj over at least 1 minute. May follow with oral doses of 0.2 to 0.4 mg 2-4 times daily until the danger of atony or haemorrhage has passed (usually 48 hr). Oral(Adult)- Postpartum and post-abortion bleeding: 0.2 to 0.4 mg 2-4 times daily until danger of uterine atony and haemorrhage has passed (usually 48 hr). Max duration: 1 wk postpartum.

Side Effects

Nausea, vomiting, abdominal pain, diarrhoea; headache, dizziness; tinnitus; chest pain, palpitation, bradycardia, transient hypertension and other cardiac arrhythmias; dyspnoea, sometimes rashes, shock

Precaution

Breech and abnormal foetal presentation; hypertension; chronic anaemia; hepatic, renal, respiratory or cardiac impairment; toxemia; lactation; hypocalcaemia. Monitor BP, pulse and uterine response.

Interaction

Halothane causes relaxation of uterine muscle and may interfere with ergometrine action. Enhanced uterotonic effect with prostaglandins and oxytocin. Concurrent admin with CYP3A4 inhibitors may lead to vasospasm, cerebral ischaemia and/or ischaemia of extremities.

Pregnancy & Breastfeeding use

Pregnancy Category X. Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

Contraindication

Pregnancy, 1st and 2nd stage of labour, patients with preeclampsia, eclampsia or threatened spontaneous abortion; porphyria.

Acute Overdose

Symptoms include peripheral vasoconstriction, encephalopathy, convulsions, respiratory failure, acute renal failure and temporary lactose intolerance. Treatment is supportive.

Storage Condition

Intramuscular: Active management of the third stage of labour: Refrigerate at 2-8°C.Intravenous: Refrigerate at 2-8°C.Oral: Store below 25°C.

Innovators Monograph